Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis
A Multi-center, Single-blind, Parallel-design, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate Oral Recombinant Microbial Lipase Efficacy in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis
Sponsor: Solvay Pharmaceuticals
Terminated
This trial discontinued March 7,2009 due to high screen failure rate.
Other terminated trials from Solvay Pharmaceuticals
This PHASE2 trial investigates Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis and is currently terminated or withdrawn. Solvay Pharmaceuticals leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Solvay Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bialystok, Poland , Brno, Czechia , Budapest, Hungary , Békéscsaba, Hungary , Daugavpils, Latvia , Debrecen, Hungary , Dunaújváros, Hungary , Eger, Hungary , Gdansk, Poland , Gothenburg, Sweden and 27 more locations